Results 81 to 90 of about 646,520 (340)

The role of complement in the clinical course of hepatocellular carcinoma

Immunity, Inflammation and Disease, 2022
Background The complement system, an innate immune system, may either play an antitumor role, or promote tumorigenesis and cancer progression in different kinds of cancer. The function of complement in hepatocellular carcinoma (HCC) is unclear.
Xinye Qian, Zhoujing Yang, Lu Gao, Yipiao Liu, Jun Yan   +4 more
doaj   +1 more source

Plasma inflammatory cytokines and survival of pancreatic cancer patients. [PDF]

, 2018
OBJECTIVES: Inflammation and inflammatory conditions have been associated with pancreatic cancer risk and progression in a number of clinical, epidemiological, and animal model studies.
Babic, A., Barbie, D. A., Brais, L. K., Fuchs, C. S., Kulke, M. H., Morales-Oyarvide, V., Neupane, N. P., Ng, K., Poole, E. M., Rifai, N., Rubinson, D. A., Schnure, N., Welch, M. W., Wolpin, B. M., Wong, K., Yuan, C., Zaman, M. M., Zhang, S.   +17 more
core   +2 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Risk factors for suicide in patients with pancreatic ductal adenocarcinoma: A population‐based study

Aging and Cancer
Background Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) face a notable risk of suicide. However, comprehensive population‐based studies on suicide risk in PDAC patients have been lacking. This study seeks to explore the suicide risk in
Chao Wang, Haoda Chen, Yuanchi Weng, Xiaxing Deng, Weishen Wang, Baiyong Shen   +5 more
doaj   +1 more source

Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

Military Medical Research, 2022
Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance, highlighting the necessity ...
Xing Huang, Gang Zhang, Tian-Yu Tang, Xiang Gao, Ting-Bo Liang   +4 more
doaj   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

mRNA vaccines in disease prevention and treatment

Signal Transduction and Targeted Therapy, 2023
mRNA vaccines have emerged as highly effective strategies in the prophylaxis and treatment of diseases, thanks largely although not totally to their extraordinary performance in recent years against the worldwide plague COVID-19.
Gang Zhang, Tianyu Tang, Yinfeng Chen, Xing Huang, Tingbo Liang   +4 more
doaj   +1 more source

Nucleosomes in pancreatic cancer patients during radiochemotherapy [PDF]

, 2005
Nucleosomes appear spontaneously in elevated concentrations in the serum of patients with malignant diseases as well as during chemo- and radiotherapy. We analyzed whether their kinetics show typical characteristics during radiochemotherapy and enable an
Amoura Z, Andreas Kremer, Arends MJ, Dietrich Seidel, Dorothea Nagel, Gauthier VJ, Heinemann V, Holdenrieder S, Ishii H, Kerr JF, Kuroi K, Lo YM, Meyn RE, Petra Stieber, Ralf Wilkowski, Rumore P, Stefan Holdenrieder, Szumiel I, Wilkowski R, Wyllie AH   +19 more
core   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source